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Abstract:
Background and objective: We evaluated the rates of  vancomycin-resistant enterococci (VRE) colonization and VRE-
related bacteremia in patients with hematological malignancies in terms of  routine screening culture and its cost-effective-
ness.
Materials and Methods: All patients of  the hematology department who were older than 14 years of  age and who devel-
oped at least one febrile neutropenia episode during chemotherapy for hematological cancers between November 2010 and 
November 2012 were evaluated retrospectively.
Results: We retrospectively analyzed 282 febrile episodes in 126 neutropenic patients during a two-year study period. The 
study included 65 cases in the first study-year and 78 cases in the second study-year. The numbers of  colonization days and 
colonized patient were748 days of  colonization in 29 patients (44%) in the first study-year and 547 colonization days in 21 
patients (26%) in the second study-year, respectively. Routine screening culture for VRE cost $4516,4 (427 cultures) in the 
first study-year, $5082,7 (504 cultures) in the second study-year depending on the number of  patients and their length of  
stay.
Conclusion: In line with our study results, routine screening of  hematological patients for VRE colonization is not cost-
effective. Routine surveillance culture for VRE should be considered with respect to the conditions of  health care setting.
Keywords: Hematological patients, febrile neutropenia, vancomycin-resistant enterococci, vancomycin-sensitive enterococ-
ci, bacteremia, colonization.
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Introduction
Enterococci are part of  the normal flora of  humans 
and vertebrate animals. They can survive under diffi-
cult conditions and varied environments, such as in soil, 
water, and food and on medical devices1. Enterococci 
are found in the gastrointestinal tract, in oropharyngeal 
secretions, and on the skin1. Vancomycin-resistant en-
terococci (VRE) can persist on dry surfaces for days 
to months, contributing to the spread of  VRE among 
patients2. These bacteria can cause nosocomial infec-
tions in vulnerable patients who are colonized with 
VRE or exposed to contaminated tools or medical 
staff3. Advanced age, severity of  illness, inter- institu-
tional transfer of  the patient, prolonged hospital stay, 
gastrointestinal surgery, transplantation, exposure to 
medical devices, especially central venous catheters, 
and heavy exposure to broad-spectrum antimicrobial 
drugs are risk factors for colonization and infection 
with VRE4. In addition, contact with contaminated 
health care workers, patients, attendants, environmental 
surfaces and equipment promotes VRE colonization5. 
Colonization of  the rectum with VRE was reported 
to be a more important predictor than colonization of  
other regions6. VRE is also an important nosocomial 
pathogen in hematological patients7. Patients who have 
hematological malignancies during remission-induction 
chemotherapy and undergo allogeneic hematopoietic 
stem cell transplantation with prior conditioning chem-
otherapy are at risk of  infection with colonizing and 
opportunistic microorganisms8. Only mucositis and 
increasing mucositis have been reported as independ-
ent risk factors for VRE-related bloodstream infection 
(BSI)9. Enterococcal bacteremia is the third or fourth 
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most common cause of  nosocomial bacteremia, with 
increasing rates worldwide8.
In this study, we retrospectively evaluated the rates of  
vancomycin-resistant enterococci (VRE) colonization 
and VRE-related bacteremia in patients with hemato-
logical malignancies in terms of  routine screening 
culture and its cost-effectiveness.
Material and Methods
Study population: All patients in the hematology 
department who were older than 14 years of  age and 
developed febrile neutropenia (FN) during chemother-
apy for hematological cancers between November 2010 
and November 2012 were evaluated in this retrospec-
tive study. The study period was divided into two pe-
riods: the "first study-year" was from November 2010 
to November 2011, and the "second study-year" was 
from November 2011 to November 2012. Due to the 
fact that some patients were treated in the first and sec-
ond study- years, the total number of  patients differs 
from the sum of  the number of  patients in the first 
and second study-years. This study was approved by the 
local ethics committee. Patients were included if  they 
had experienced at least one neutropenic episode due 
to chemotherapy in the hematology ward. Meanwhile, 
patients were excluded if  they were treated for other he-
matological diseases (e.g., anemia, idiopathic or immune 
thrombocytopenic purpura, etc.).
Prevention of  drug-resistant infections: The hema-
tology department was equipped with 23 beds in single, 
double and four-person rooms without high-efficiency 
particulate air filters. Patients and their attendants resid-
ed in the same room and used three shared toilets in the 
hematology ward. In both study periods, a weekly one-
hour instructional program regarding drug-resistant 
microorganisms and preventative measures was admin-
istered to patients and their attendants by a nurse and a 
doctor in the hematology ward.  The instructional pro-
gram promoted the use of  alcohol-based hand disin-
fectant after contact with materials and zones that were 
contaminated or likely to be contaminated. Patients 
who were colonized with VRE underwent cohorting. 
Healthcare workers were required to use gloves when 
entering the room and gloves and gown when contact 
with body fluids was anticipated. Hospital floors were 
cleaned daily with a 1000 parts per million (ppm) solu-
tion of  sodium hypochlorite10. The use of  glycopeptide 
and anti-anaerobic antibiotics were restricted according 
to the 2002 clinical practice guidelines for the use of  an-
timicrobial agents in neutropenic patients with cancer, 
the 2010 update by the Infectious Diseases Society of  
America, and the European Organization for Research 
and Treatment of  Cancer/Invasive Fungal Infections 
Cooperative Group and the National Institute of  Aller-
gy and Infectious Diseases Mycoses Study Group (EO-
RTC/MSG) guidelines.11-13 All procedures were strictly 
implemented during the first and second year periods 
without any additional interventions.
Diagnosis of  FN: FN was defined as an oral tempera-
ture >38.3°C or two consecutive readings>38.0°C for 2 
h and an absolute neutrophil count <0.5 × 10^9/L or a 
count expected to fall below 0.5 × 10^9/L.11 Collected 
data included patient demographics and diagnoses, the 
episode data, clinical presentation and laboratory find-
ings, clinical therapy, microbiological data, interven-
tions, invasive procedures and outcomes. The treatment 
protocol for FN in our hospital was based on the afore-
mentioned guidelines11-13. Blood samples drawn from a 
vein or a catheter were inoculated into BactAlert 3D 
bottles (bioMérieux, Marcy-L’Etoile, France). Addition-
al samples, such as urine, sputum, wound, conjunctive, 
abscess, and catheter samples, were inoculated onto 5% 
sheep blood agar (Salubris Inc., Istanbul, Turkey),
chocolate agar (Salubris Inc.) and MacConkey agar (Sa-
lubris Inc.). Identification and susceptibility testing were 
performed using an automated broth microdilution 
method (Vitek2, bioMérieux, Marcy-L’Etoile, France), 
and confirmations were made by the E test method (AB 
BIODISK, Solna, Sweden). The breakpoints defined by 
the Clinical and Laboratory Standards Institute (CLSI, 
2008) were used. VRE colonization was detected by 
inoculation of  rectal swabs onto a bile-esculin-azide 
agar plate containing 6 µg/ml of  vancomycin (Becton, 
Dickinson and Company, Sparks, MD, USA). Plates 
were then incubated aerobically at 5 to 10% CO2 at 
35 to 37°C for up to 48 hours (for confirmation of  a 
negative result). Samples were collected from patients at 
two-week intervals.
VRE-related outcomes: The number of  coloniza-
tion days with VRE was calculated as the number of  
days with positive rectal swab cultures. The coloniza-
tion period was considered to have ended when two 
rectal swab cultures, which were taken at an interval of  
two weeks, were negative without clinical or radiologic 
findings associated with VRE11. Strains isolated from 
cultures that were defined as contaminated by infec-
tious disease specialists or medical microbiologists were 
excluded from the study.  Patients with VRE bacteremia 
were treated with linezolide (2x600 mg/day) for at least 
14 days. 
Patients with VSE were treated with ampicillin-sul-
bactam (8-12 gr/day) plus gentamycin (160-240 mg/
day) for at least 14 days. A positive response to treat-
ment was defined as defervescence in the 48-72 hours 
subsequent to initiation of  antimicrobial therapy and 
improvements in vital signs and clinical symptoms as-
sociated with infection (e.g., improvement in arterial 
blood-gas values, radiological improvement, negative 
urine culture for urinary tract infection and recovery of  
signs and symptoms related to other infections). The 
VRE infection rate for patients colonized with VRE 
during the neutropenic phase was the primary outcome 
of  this study. The mortality rate due to VRE-related 
infection was the secondary outcome of  this study.
Posaconazole (POS) was used for primary antifungal 
prophylaxis as given 200 mg per oral three times in 
a day with fat meal and acidic fruit juice during a pe-
riod a time that neutrophil count decreased to below 
1×10^9/L subsequent to chemotherapy until recov-
ered to 1×10^9/L. Secondary antifungal prophylaxis 
was administered to patients who were treated with 
IPA diagnosed clinically or microbiologically developed 
subsequent to previous chemotherapy as voriconazole 
(VOR)  200 mg twice in a day per oral or POS 200 mg 
three times in a day during a period a time that neutro-
phil count decreased to below 1×10^9/L subsequent to 
chemotherapy until recovered to 1×10^9/L. If  patient 
could not receive oral therapy, secondary antifungal 
prophylaxis was given intravenously. Antibiotic prophy-
laxis was administered to any patients.
Statistical analysis: Continuous variables were repre-
sented as the mean ± standard deviation and the range. 
Percentile values were represented without decimals. 
Overall mortality associated with febrile neutropenia 
was defined as death within 30 days of  the develop-
ment of  neutropenia. Crude 30-day mortality rates were 
calculated as the proportion of  study patients who died 
within 30 days of  the development of  neutropenia. The 
cost of  screening cultures had been calculated as con-
verting of  the price that had been billed to the Republic 
of  Turkey Social Security Institution per culture on the 
U.S. dollar exchange rate.
Results
We retrospectively analyzed 282 febrile episodes in 126 
consecutive patients with neutropenia excluding 15 of  
141 patients who were not eligible for study criteria 
during a two-year study period. The study included 65 
cases in the first study-year and 78 cases in the second 
study- year. The mean patient age was 51.73 ± 14.4 
years (range: 17–82 years), and 66 cases were male pa-
tients. The MASCC score was 17.18 ± 8.27 in patients 
with hematological malignancies (Table 1). 
Table 1. Distribution of  hematologic malignancies in patients with febrile 
neutropenia (n=126)
 
Hematologic Malignancies n (%) 
Acute myeloblastic leukemia 73 (58) 
Acute lymphocytic leukemia 22 (17) 
Non-Hodgkin’s lymphoma 7 (5) 
Chronic lymphocytic leukemia 5 (4) 
Multiple myeloma 5 (4) 
Hairy cell leukemia 4 (3) 
Aplastic anemia 3 (2) 
Chronic myeloid leukemia 2 (2) 
Plasma cell leukemia 2 (2) 
Mantle-cell lymphoma 2 (2) 
Chronic lymphocytic leukemia 
with Burkitt's lymphoma 
1 (1) 
Total 126 (100) 
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The vancomycin-resistant enterococcal species iso-
lated from VRE- colonized patients were Enterococ-
cus faecium (81%) and Enterococcus faecalis (19%). 
The mean number of  VRE colonization days per pa-
tient was 34.27 ± 13.12 days.  Among the 50 patients 
colonized with VRE, VRE bacteremia developed in 2 
(4%) patients during a total of  1,295 colonization days 
in two study-years. The numbers of  colonization day 
and colonized patients were748 days of  colonization in 
29 patients (44%) in the first study-year and 547 colo-
nization days in 21 patients (26%) in the second study-
year, respectively. During the first study-year, no cases 
of  VRE bacteremia developed. Vancomycin-sensitive 
E. faecium was also isolated from wound (n=1), urine 
(n=1) and sputum (n=1) cultures. VRE bacteremia was 
observed in a patient who was admitted with pneumo-
nia as being transferred from a hospital.
Enterococcus faecium was isolated from broncho-alve-
olar lavage and blood cultures, but rectal swab cultures 
yielded normal flora bacteria. That patient with VRE 
bacteremia was successfully treated with linezolid. In 
the second study-year, VRE bacteriemia developed in 
a male patient who recovered from infection under sal-
vage chemotherapy due to non-Hodgkin’s lymphoma 
and a female patient who died of  VRE bacteremia un-
der consolidation chemotherapy due to acute myeloid 
leukemia (AML). Enterococcus faecium was isolated
from blood cultures of  both cases. In addition, VSE-
related bacteremia (n = 6), bacteriuria (n= 2), sputum (n 
= 1), and wound (n = 1) were observed in nine patients. 
Of  those seven patients, four were male, and the me-
dian age was 44 years (range: 25-73). VSE-related bac-
teremia attacks were caused by E. faecalis (n = 4) and E. 
faecium (n = 2) in the patients receiving consolidation 
chemotherapy. 
Vancomycin-sensitive E. faecalis was isolated from 
the patient with bacteriuria. The hematological malig-
nancies in the patients with VSE-related bacteremia 
and bacteriuria were AML (n=3), acute lymphocytic 
leukemia (ALL) (n=1), multiple myeloma (MM) (n=1), 
non-Hodgkin’s lymphoma (NHL) (n=1), and hairy cell 
leukemia (n=1), respectively. Two patients who had 
VSE- related bacteremia died.  Only two patients who 
had persistent fever accompanied by distinctive clinical 
findings (e.g., cough, pain in the anal region, or ulcera-
tions of  the oral mucosa) responded to linezolid treat-
ment. The placement of  a chemotherapy port catheter 
and bone marrow biopsy were the invasive procedures 
that were performed on patients colonized with VRE 
during follow-up. No case of  VRE-related bacteremia 
developed among patients who were not colonized with 
VRE.
A total of  2,574 rectal swab cultures was taken from all 
patients. Each VRE screening culture costed between 
$9.49 and $11.51 during the study period. Screening 
cultures for VRE costed between $9.49 (one culture) 
and $244.7 (25 cultures) per patient depending on 
length of  stay. Routine screening culture for VRE cost-
ed $4516.7 (427 cultures) in the first study-year, $5082,7 
(504 cultures) in the second study-year depending on 
the number of  patients and their lengths of  stay.
The overall 30-day crude mortality rates among patients 
with hematological malignancies were 35% (23/65) 
in the first study-year and 21% (17/78) in the second 
study-year. The hematological malignancies of  patients 
who died included AML (n=16), acute lymphocytic leu-
kemia (ALL, n=5), multiple myeloma (n=1), chronic 
myeloid leukemia (n=1) in the first study-year and AML 
(n=16), ALL (n=4), non-Hodgkin lymphoma (n=1) in 
the second study- year. The number of  patients who 
died of  infections was 17 (26%) in the first study-year, 
and 11 (14%) in the second study-year. Patients died of  
MRSA-related bloodstream infections (n=2), invasive 
fungal infection (n=6) and severe vancomycin-sensi-
tive E. faecium-related sepsis(n=1) in the first study-
year and Gram-negative bacteremia (n=5), VSE-related 
bacteremia (n=3), invasive fungal infection (n=2) and 




Routine screening culture for VRE costed more than 
$4500 per year, although a few cases with VRE related 
bacteriemia were observed. Although the benefits of  
surveillance cultures as being a part of  infection con-
trol measures have been reported in the studies, cost-
effectiveness of  routine VRE screening cultures in the 
hematological patients who are vulnerable to oppor-
tunistic infections have not been evaluated yet.  Infec-
tion control measures provide more saving than rou-
tine surveillance cultures14. However, screening culture 
for VRE is recommended for patients/residents who 
are at increased risk for VRE, such as previously being 
colonized or infected with VRE, being transferred from 
hospital with VRE outbreak or high VRE colonization 
or infection rates on admission. If  a patient or resident 
has been a roommate or  has been in physical contact 
with the unidentified patient or resident subsequently 
found to have VRE, at least two specimens should be 
taken on different days with one taken a minimum of  
seven days following the last exposure to VRE14. There 
is no evidence about the benefits of  screening staff  for 
VRE14. Infection control strategies, including surveil-
lance cultures supplies ($4,137) were reported to cost 
$116,515 for one year.
The savings associated with fewer VRE BSI ($123,081), 
fewer patients with VRE colonization ($2,755), and re-
ductions in antimicrobial use ($179,997) were reported 
to total $305,833. Ranges of  costs and savings were es-
timated for enhanced infection control strategies were 
$97,939 to $148,883 for costs and $271,531 to $421,461 
in savings15. And also stool specimens were reported to 
be more effective than rectal swabs16. 
There is no study regarding the cost-effectiveness of  
routine VRE surveillance culture as well. Unfavorable 
ward conditions, such as shared toilets, housing of  at-
tendants with patients, close contact between patients 
and their attendants, frequent antibiotic use for infec-
tions, and immunosuppression, were likely to be impor-
tant risk factors in terms of  higher VRE colonization 
rates in the first study-year. Reduced VRE colonization 
rates in the second year were likely to be related to in-
crease compliance of  patients and their attendants in 
the second year. VRE colonization increases in patients 
with hematological malignancies under certain condi-
tions, including immunosuppression, serious comor-
bid conditions (e.g., diabetes, renal failure, and high 
APACHE score), increased lenghth of   hospital stay, 
residence in a long-term care facility, proximity to an-
other colonized or infected patient (including sharing 
a room), hospitalization in a room previously occupied 
by a patient colonized with VRE, invasive procedures, 
and administration of  broad-spectrum antibiotics or 
vancomycin10, 17. 
Patients whose rectal swab cultures yield VRE should 
be considered positive until three consecutive negative 
cultures are obtained with at least one-week intervals, 
according to the hospital infection control practices ad-
visory committee (HICPAC) guidelines18. However, this 
approach does not guarantee complete eradication of  
VRE18. Infection control measures and instruction of  
patients and their attendants can decrease colonization 
rates in the ward and contamination of  the environ-
ment.
The number of  cases with VRE-related bacteremia in-
creased while VRE colonization rates were decreasing 
in the second year of  the study. This confounding re-
sult can be explained by risk factors, such as prolonged 
use of  intensive antimicrobial therapy, high dose cancer 
chemotherapy, severe mucositis, gastrointestinal sur-
gery, and the placement of  invasive devices, are more 
likely to promote the development of  VRE-related BSI. 
It has also been reported that VRE-related bacteremia 
has a close relationship between severity of  the patient’s 
illness and the pathogenicity of  the bacteria6. 
Subsequent to induction or consolidation chemotherapy 
impairing mucosal barriers, pathogenic microorganisms 
can invade the intravascular compartment through the 
damaged mucosa. Mucositis and increasing mucositis 
were reported to be independent risk factors for VRE-
related bloodstream infection (BSI)9. BSI rates were re-
ported from 0% to 34% in patients who are colonized 
with VRE. These rates are higher in patients with can-
cer and patients who received solid and bone marrow 
transplants. Among VRE-colonized patients, cancer or 
diabetes (relative risk (RR) = 3.91), gastrointestinal pro-
cedures (RR= 4.56), acute renal failure (RR= 3.1), ex-
posure to vancomycin (RR= 1.95), infection of  an ad-
ditional site other than the blood (Odds ratio= 3.9), and 
concurrent Clostridium difficile infection were reported 
to be risk factors for VRE-related BSI19, 20. VRE-related 
bacteremia should be considered in case persistent fe-
ver and worsening clinical signs and symptoms occur 
during febrile neutropenia episode of  patient colonized 
with VRE. 
Active VRE therapy should be initiated in these cases. 
Since mortality rates were found to be 2.5 times higher 
in patients colonized with VRE than in patients colo-
nized with VSE21, 22. Moreover, less frequent invasive 
procedures, including the placement of  chemotherapy 
port catheters and bone marrow biopsies are likely to 
be related to lower rates of  VRE-related bacteremia as 
found in our study23. Endocarditis or intestinal lesions 
should be examined in case of  persistent VRE- or VSE-
related bacteremia. Vancomycin resistance, comorbidity 
and severity of  illness decrease achievement rates20, 21.
In line with our study results, routine screening of  he-
matological patients for VRE colonization is not cost-
effective. Routine surveillance culture for VRE should 
be considered with respect to the conditions of  health 
care setting. VRE colonization precedes VRE- or VSE-
related bacteremia if  certain conditions, including the 
development of  severe mucositis, the administration 
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of  invasive procedures, and the use of  intensive broad-
spectrum antibiotics exist in patient colonized with 
VRE. 
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